The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
Tawbi et al. (2021) have recently reported that nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses (N1I3) provided durable survival for patients with active melanoma brain metastases without symptoms as first-line regimen. While we believe in the usefulness of the regimen propose...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-08-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523322001085 |
| _version_ | 1818231671998119936 |
|---|---|
| author | Takeshi Fukumoto Nobuyuki Horita |
| author_facet | Takeshi Fukumoto Nobuyuki Horita |
| author_sort | Takeshi Fukumoto |
| collection | DOAJ |
| description | Tawbi et al. (2021) have recently reported that nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses (N1I3) provided durable survival for patients with active melanoma brain metastases without symptoms as first-line regimen. While we believe in the usefulness of the regimen proposed by Tawbi et al. (2021) we sought to investigate whether the nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses (N3I1) regimen might lead to better safety profile. To compare the risk of adverse events caused by these two regimes, we have recently conducted a meta-analysis using the data of patients with both melanoma and the other malignancies. N1I3 regimen, compared to N3I1 regimen, more frequently induced any adverse events (N1I3, 96%; N3I1, 85%; P = 0.003), grade III or higher adverse events (N1I3, 64%; N3I1, 36%; P < 0.001; Fig. 1), and serious adverse events (N1I3, 61%; N3I1, 48%; P = 0.004). In terms of organ specific side effects, the N1I3 regimen also caused significantly more hepatic dysfunction, diarrhea, colitis, and pyrexia. We hope that there will be further discussion on the best dosage of the combination therapy. |
| first_indexed | 2024-12-12T10:54:06Z |
| format | Article |
| id | doaj.art-4895eec84c994e769fc570aa1bc6f4bc |
| institution | Directory Open Access Journal |
| issn | 1936-5233 |
| language | English |
| last_indexed | 2024-12-12T10:54:06Z |
| publishDate | 2022-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-4895eec84c994e769fc570aa1bc6f4bc2022-12-22T00:26:42ZengElsevierTranslational Oncology1936-52332022-08-0122101449The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastasesTakeshi Fukumoto0Nobuyuki Horita1Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho Hyogo Chuo-ku, Kobe, 650-0017, Japan; Corresponding author.Chemotherapy Center, Yokohama City University Hospital, Yokohama, JapanTawbi et al. (2021) have recently reported that nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses (N1I3) provided durable survival for patients with active melanoma brain metastases without symptoms as first-line regimen. While we believe in the usefulness of the regimen proposed by Tawbi et al. (2021) we sought to investigate whether the nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses (N3I1) regimen might lead to better safety profile. To compare the risk of adverse events caused by these two regimes, we have recently conducted a meta-analysis using the data of patients with both melanoma and the other malignancies. N1I3 regimen, compared to N3I1 regimen, more frequently induced any adverse events (N1I3, 96%; N3I1, 85%; P = 0.003), grade III or higher adverse events (N1I3, 64%; N3I1, 36%; P < 0.001; Fig. 1), and serious adverse events (N1I3, 61%; N3I1, 48%; P = 0.004). In terms of organ specific side effects, the N1I3 regimen also caused significantly more hepatic dysfunction, diarrhea, colitis, and pyrexia. We hope that there will be further discussion on the best dosage of the combination therapy.http://www.sciencedirect.com/science/article/pii/S1936523322001085Best dosageNivolumabIpilimumabMelanoma |
| spellingShingle | Takeshi Fukumoto Nobuyuki Horita The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases Translational Oncology Best dosage Nivolumab Ipilimumab Melanoma |
| title | The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases |
| title_full | The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases |
| title_fullStr | The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases |
| title_full_unstemmed | The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases |
| title_short | The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases |
| title_sort | best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases |
| topic | Best dosage Nivolumab Ipilimumab Melanoma |
| url | http://www.sciencedirect.com/science/article/pii/S1936523322001085 |
| work_keys_str_mv | AT takeshifukumoto thebestdosageofnivolumabplusipilimumabcombinationformelanomabrainmetastases AT nobuyukihorita thebestdosageofnivolumabplusipilimumabcombinationformelanomabrainmetastases AT takeshifukumoto bestdosageofnivolumabplusipilimumabcombinationformelanomabrainmetastases AT nobuyukihorita bestdosageofnivolumabplusipilimumabcombinationformelanomabrainmetastases |